Mergers and acquisitions – Page 10
-
BusinessMerger creates new gases giant
Air Liquide will buy Airgas in a $13 billion deal to become the world’s biggest industrial gases supplier
-
BusinessPfizer and Allergan agree mega-merger
$160 billion deal allows Pfizer to escape US tax system by re-homing in Ireland
-
Business
AstraZeneca to buy ZS Pharma for ion-balance drugs
$2.7 billion deal anticipates regulatory success for drug candidate under review
-
Business
Samsung to sell chemicals businesses to Lotte
Korean conglomerate Lotte will pay £1.7 billion for stake in Samsung’s chemicals businesses
-
Business
Dow backs off of Kuwaiti joint ventures
EQUATE will acquire MEGlobal as part of Dow’s restructuring of its Kuwaiti joint ventures
-
Business
Shire to buy rare disease specialist Dyax
Deal includes an already-approved drug for angioedema and an experimental antibody treatment
-
Business
Bristol-Myers Squibb to buy Cardioxyl for heart drug
Deal worth up to $2bn gives BMS full rights to Phase II clinical candidate
-
Business
BMS agrees $1.7bn immuno-oncology collaboration
Deal strengthens cancer antibody alliance with Five Prime Therapeutics
-
Business
Amgen expands cardiovascular portfolio with Dezima acquisition
Amgen’s $300 million purchase of Dutch biotech gives the company the potential to offer more varied treatment options to lower cholesterol
-
BusinessMerger fever sweeps pharma
The life sciences sector has been gripped by a mergers and acquisition frenzy, and it looks set to continue. But what does it mean for the industry?
-
Business
Syngenta to sell off seed business after failed Monsanto takeover
Syngenta to restore shareholder confidence following a series of failed takeover bids by Monsanto
-
Business
Novartis to buy experimental MS drug from GSK in $1bn deal
Deal will help to bolster Novartis’s pipeline for neurological disorder treatments
-
Business
Syngenta fends off Monsanto takeover bid
Unmoving objection to merger leads US giant to drop pursuit
-
Business
Shire makes hostile bid for Baxalta
Recently spun-out from Baxter, Baxalta is resisting the deal, saying it wants time to prove its true value
-
Business
Grabbing slices of the immuno-oncology pie
Another spate of immuno-oncology dealmaking adds to fervour in pharma’s ‘hottest space’
-
Business
Berry plastics to buy Avintiv for $2.5bn
Deal helps Berry diversify from food packaging into speciality medical materials
-
Business
AstraZeneca sells off drugs to streamline portfolio
Crohn’s disease and rare thyroid cancer drugs lie outside firm’s renewed strategic focus
-
Business
Lightweight composites drive Solvay to buy Cytec
$5.5bn deal launches Solvay into aerospace materials business
-
Business
Celgene to buy immune-inflammatory specialist Receptos
$7.2bn deal further strengthens Celgene’s position in immunology
-
Business
Hikma boosts generics with Roxane buyout
Acquiring the Boehringer Ingelheim subsidiary expands Hikma’s presence in US generics market